Antibody Mediated Rejection Market 2024: Global Scope, Industry Growth, Competitive Analysis, and Forecast to 2031 - CSL Behring, Hansa Biopharma, Novartis AG, Talaris Therapeutics, Amgen Inc

DataM Intelligence has released a new research report on the Antibody Mediated Rejection market. The report provides a detailed analysis of current and emerging trends, offering insights into the market dynamics. It utilizes Porter's Five Forces model to assess key factors such as supplier and customer relationships, risks from various agents, competitive intensity, and opportunities for new entrants. The study also includes research data from various companies, analyzing factors like benefits, gross margins, and strategic decisions in the global market. The report is enriched with tables, charts, and infographics for a clear presentation of the findings.

The Global Antibody-Mediated Rejection (AMR) Market reached at a CAGR of 6.3% during the forecast period 2024-2031.

Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/antibody-mediated-rejection-market

Antibody-mediated rejection (AMR) is a form of transplant rejection that occurs when the recipient's immune system produces antibodies against the donor's antigens, leading to damage and dysfunction of the transplanted organ or tissue. This type of rejection is primarily mediated by B cells, which produce specific antibodies targeting foreign antigens present on the surface of the donor cells. AMR can occur in both acute and chronic forms and may result in inflammation, vascular injury, and ultimately, transplant failure if not adequately managed. It is a critical consideration in transplantation medicine, necessitating careful monitoring and immunosuppressive therapy to prevent or mitigate its effects.

List of the Key Players in the Antibody Mediated Rejection Market:

CSL Behring, Hansa Biopharma, Novartis AG, Talaris Therapeutics, Amgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd, Ltd. and Biogen

Key Developments:

On May 9, 2024, researchers from MIT, Brigham and Women's Hospital, and Harvard Medical School announced the development of a promising new treatment for alopecia areata, an autoimmune disorder characterized by hair loss that affects individuals of all ages, including children.

On August 10, 2023, the PPD clinical research division of Thermo Fisher Scientific Inc., a global leader in scientific services, received a five-year award to establish a Transplantation Statistical and Clinical Coordinating Center for the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health in the United States.

On November 28, 2022, Hansa Biopharma revealed positive topline results from the phase 2 study of imlifidase for treating antibody-mediated rejection (AMR) episodes following kidney transplantation.

On March 16, 2022, the Independent Data Monitoring Committee recommended the early halt of the evaluation of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).

On February 1, 2021, Horizon Therapeutics acquired Viela Bio, an AstraZeneca spinout, for $3 billion. This acquisition is anticipated to enhance Horizon's portfolio of clinical-phase drug candidates for autoimmune and inflammatory disorders, as well as strengthen its research and development capabilities and access to an authorized monoclonal antibody.

Research Process:

Both primary and secondary data sources have been used in the global Antibody Mediated Rejection Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Segment Covered in the Antibody Mediated Rejection Market:

By Treatment: Corticosteroids, Biologics, Immunosuppressants, Plasmapheresis, Others

By Route of Administration: Injectable, Oral, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/antibody-mediated-rejection-market

Regional Analysis:

➣ North America (US, Canada, Mexico)

➣ Europe (Germany, Russia, UK, France, Italy, Spain, Rest of Europe)

➣ Asia-Pacific (China, India, Japan, Australia, Rest of Asia Pacific)

➣ South America (Brazil, Argentina, Rest of South America)

➣ Middle East and Africa

**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Antibody Mediated Rejection market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Antibody Mediated Rejection Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Antibody Mediated Rejection market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Antibody Mediated Rejection Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/antibody-mediated-rejection-market

The Research Report Offers Answers To The Following Questions:

☛ What is the expected growth rate of the global market for the forecast period?

☛ What are the key driving factors that are responsible to shape the fate of the Antibody Mediated Rejection market during the forecast period?

☛ What will be the overall size of the market during the analysis period?

☛ What are the prominent market trends which influence the development of the Antibody Mediated Rejection market across various regions?

☛ Who are the key market players and the market strategies that have helped them to secure the leading position in the global market?

☛ What are the challenges and threats that are likely to act as a barrier to the growth of the Antibody Mediated Rejection market?

☛ What are the major opportunities that the companies can get to attain success in the world?

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.